Autolus Therapeutics (FRA:6A3A) Moat Score: 5/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
68 GF Score
Price €1.32
GF Value €18.17
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics Moat Score?

Autolus Therapeutics FRA:6A3A +6.45% 68 Moat Score is 5 as of Jul. 26, 2026. GuruFocus rates FRA:6A3A with a GF Score™ of 68/100 and a GF Value™ of €18.17 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,395 Biotechnology companies, Autolus Therapeutics ranks better than 96.7% on this metric.

Autolus Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Autolus Therapeutics has Narrow Moat: Autolus Therapeutics has a solid narrow moat due to its valuable intellectual property and R&D capabilities in the biotech sector. However, it faces significant competition and regulatory challenges, limiting its market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Autolus Therapeutics might have Narrow Moat - Solid narrow moat.

Autolus Therapeutics  (FRA:6A3A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Autolus Therapeutics Moat Score Related Terms

FRA:6A3A vs FBRX, SGMT, EDIT: Moat Score Comparison

For the Biotechnology subindustry, Autolus Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's Moat Score falls into.


FRA:6A3A
68GF Score
Autolus Therapeutics PLC FRA:6A3A
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Autolus Therapeutics (FRA:6A3A) has a Moat Score of 5 as of Jul. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Autolus Therapeutics ranks #46 out of 1395 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Autolus Therapeutics' Moat Score too high?
Autolus Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Autolus Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, Autolus Therapeutics ranks #46 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Autolus Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Moat Score compare to FBRX and SGMT?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #46 out of 1395 companies for Moat Score. This places Autolus Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Autolus Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autolus Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autolus Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €18.17, compared to a current price of €1.32 — trading 92.7% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Autolus Therapeutics' overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Moat Score is 5 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.32 is trading 92.7% below its estimated GF Value™ of €18.17. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • Moat Score: 5
  • GF Value™: €18.17 vs. price of €1.32 (92.7% below fair value)
  • GF Score™: 68/100 with 7 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1395)

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for FRA:6A3A

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.32
Price
€18.17
GF Value